Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961726 | 0.74 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL471865 | 0.74 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL961378 | 0.72 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| Hydrogen Sulfide SCHEMBL721911 | 0.71 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL11740603 | 0.70 | — | — | |
| SCHEMBL19612832 | 0.69 | — | — | |
| SCHEMBL2778023 | 0.69 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL11743173 | 0.69 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL2782843 | 0.67 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1AGMNN | |
| SCHEMBL20878701 | 0.65 | MEN1 (0.38) | ADRA2AADRA2BADRA2CADRA1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816944-A | Anti-filovirus compounds and uses thereof | 中山大学 | 2021-12-21 | — | — | CN | disclosed |
| CN-111278825-A | Diazaspiro ROCK inhibitors | 百时美施贵宝公司 | 2020-06-12 | — | — | CN | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | ADRA2A 1460/4885ADRA2B 1068/4885ADRA2C 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.